Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to Icosavax shareholders. The tender offer in connection with the proposed transaction is currently set to expire on or around January 26, 2024.

Halper Sadeh encourages Icosavax shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Icosavax and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Icosavax shareholders; (2) determine whether AstraZeneca is underpaying for Icosavax; and (3) disclose all material information necessary for Icosavax shareholders to adequately assess and value the merger consideration. On behalf of Icosavax shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Icosavax shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103840066/en/